Review Article
A Brief Review on Medicinal Plants-At-Arms against COVID-19
Table 1
Vaccines under trial for COVID-19, their types, effectiveness, dosage, and storage.
| Companies | Country | Name | Type | Trials | Approval | Effective (%) | Dose/gap period (days apart) | Storage/duration (days/weeks) | Reference |
| FBRI | Russia | EpiVacCorona | Peptide antigens-based | 03 | 01 | 100 | 2X/21–28 d | 2° to 8°C | [5, 6] | Moderna | USA | mRNA-1273 | Lipid nanoparticle (LNP)-encapsulated mRNA | 07 | 40 | 94.1 | 2X/28–42 d | 2° to 8°C/30 d | [7, 8] | Pfizer/BioNTech | Germany USA | BNT162b2 | Lipid nanoparticle (LNP) formulated, nucleoside modified RNA vaccine | 12 | 68 | 95 | 2X/21 d | −25°C to −15°C/2 weeks | [9] | CanSino | China | Ad5-nCoV | Nonreplicating viral vector | 06 | 032 | 65.7–91% | Single dose | 2° to 8°C | [10] | Gamaleya | Russia | Sputnik V | Nonreplicating viral vector | 19 | 45 | 91.6–100 | 2X/21 d | 2° to 8°C | [11] | Janssen (Johnson & Johnson) | USA | Ad26.COV2.S | Nonreplicating viral vector | 08 | 04 | 66–85 | Single dose | 2°to 8°C/3 months | [12] | Oxford/AstraZeneca | UK | AZD1222 | Nonreplicating viral vector | 22 | 74 | 81.3 | 2X/12 weeks | 2° to 8°C/6 months | [13] | Serum Institute of India | India | Covishield | Nonreplicating viral vector | 02 | 17 | 81.3 | 2X/12 weeks | 2° to 8°C/6 months | [13] | Bharat Biotech | India | Covaxin | Inactivated | 0 | 03 | 81 | 2X/21 d | 2° to 8°C | [14] | Sinopharm (Beijing) | China | BBIBP-CorV | Inactivated | 06 | 20 | 79 | 2X | 2° to 8 °C | [15] | Sinopharm (Wuhan) | China | Inactivated (vero cells) | Inactivated | 06 | 02 | 72.51 | 2X | 2° to 8°C | [16] | Sinovac | China | CoronaVac | Inactivated | 13 | 16 | 50.4–100 | 2X | 2° to 8°C | [17] | AstraZeneca | Sweden | Vaxzevria | mRNA vaccine | 03 | 121 | 74 | 2X/12 weeks | 2° to 8°C | [18] | Novavax | USA | Nuvaxovid | Recombinant protein vaccine | 03 | — | 90.4 | 2X/8 weeks | 2° to 8°C | [19] |
|
|